Psychiatric Medications and Pregnancy: A Practical Guide to Staying Safe, Stable, and Informed

Pregnancy reshapes your body, your sleep, your fears, and sometimes your psychiatric medications. This guide helps you stay stable, protected, and well-supported—before pregnancy, during it, and after your baby arrives.

A patient sat twelve weeks into her pregnancy, turning a bottle of sertraline between her fingers. “Tell me I’m not poisoning my baby,” she said. We’ve heard versions of that sentence for years. A medication that felt like a lifeline a month ago can look like a toxin the day a pregnancy test turns positive.

But the decision is rarely as simple as “stay on it” or “stop it.”

You are not choosing between “risk” and “no risk.”

You are choosing between:

• the risks of continuing,

• the risks of stopping, and

• the risks of untreated illness

Untreated depression, anxiety, ADHD, or bipolar disorder can affect sleep, nutrition, bonding, safety, and prenatal care. Your mental health is not separate from prenatal care—it is part of prenatal care.

And while this guide uses the term “woman,” we recognize that transgender and non-binary people can also become pregnant and deserve affirming, coordinated care.

Before Pregnancy: Your Most Flexible Window

The months before pregnancy offer the most breathing room. There is time to taper (gradually lower) if appropriate, time to switch medications if a safer option exists, and time to stabilize well before conception.

Who Sometimes Does Well Tapering 

We see a consistent pattern in people who taper successfully:

• one prior depressive episode tied to a major stressor

• years of stability

• strong psychological and social supports

• no history of suicidality or psychosis

• predictable sleep and routine

These individuals sometimes do well with a slow taper under close supervision with their doctor.

Who Usually Does Best Staying on Medication

Another pattern is equally clear:

• recurrent major depression

• bipolar disorder

• prior postpartum psychosis

• past suicide attempts

• multiple failed trials before finding the right medication

In these situations, tapering carries relapse rates in the 50–70% range, often quickly.

Medication and Fertility

Most psychiatric medications do not impair fertility. One important exception is risperidone (Risperdal) and some other prolactin-raising antipsychotics, which can disrupt ovulation. Fortunately, this effect is usually reversible once the medication is changed.

When Switching Makes Sense

Some medications carry well-documented pregnancy risks:

• Valproate (Depakote): neural tube defects (5–10%), cognitive effects

• Carbamazepine (Tegretol): neural tube defects (~0.5–1%)

• Paroxetine (Paxil): small increase in certain cardiac defects

If switching is needed, it takes time: tapering the old medication, introducing the new one, then maintaining full stability for several months—often a 3–6 month process.

Protective Non-Medication Factors

• therapy (especially CBT - Cognitive behavioral therapy or IPT - Interpersonal psychotherapy)

• consistent sleep routines

• regular exercise

• omega-3 supplementation (EPA ≥ 1000 mg/day)

These do not replace medication when illness is severe, but they can meaningfully lower relapse risk.

When Your OB Says “Stop Everything”

Some obstetricians still say this reflexively. When it happens, ask them to speak directly with your psychiatrist. In many cases, miscommunication between clinicians is more dangerous than any single medication decision.

Before pregnancy, ask your psychiatrist:

• What is my personal relapse risk if we taper?

• Do any medications affect ovulation?

• If we switch, what is the stabilization timeline?

• What is the plan if symptoms return once I’m pregnant?

During Pregnancy: Managing Risks and Staying Stable

Pregnancy changes how the body handles medication. Blood volume increases, liver enzymes speed up metabolism, kidneys filter more efficiently. A dose that worked six months ago may be too low by mid-pregnancy.

Understanding Baseline Risk

Every pregnancy carries a 3–4% baseline risk of major birth defects, even when no medications are involved. That’s why headlines about a “50% increase in risk” can be misleading—this usually means the risk rises from about 3% to 4.5%, not from safe to dangerous.

Antidepressants

Sertraline (Zoloft), escitalopram (Lexapro), and fluoxetine (Prozac) have the strongest safety data. Large registries show no meaningful increase in major malformations. Bupropion (Wellbutrin), mirtazapine (Remeron), SNRIs like duloxetine (Cymbalta) and effexor (Venlafaxine), and TCAs like nortriptyline (Pamelor) and amitriptyline (Elavil) are also broadly reassuring.

Paroxetine carries a small but real increase in certain cardiac defects. But if paroxetine is the only drug that has ever worked, staying on it may still be safer than destabilizing a severe illness.

Autism and ADHD fears have persisted for years. Large 2023–2024 studies show that once maternal illness severity and family history are accounted for, the apparent link disappears.  This means the increased risk comes from the underlying illness, not the medication.

Mood Stabilizers

• Lamotrigine: levels fall up to 50%; without dose increases, relapse is common.

• Lithium: small absolute increase in Ebstein’s anomaly; requires levels + fetal echo.

• Valproate: highest risk; avoid if possible.

• Carbamazepine: neural tube defect rate around 0.5–1%.

Antipsychotics

Quetiapine (Seroquel) is widely used and well tolerated. Aripiprazole (Abilify) may be activating. Olanzapine (Zyprexa) increases metabolic risk. Risperidone (Risperdal) may interfere with ovulation before pregnancy.

Benzodiazepines

Increased cleft-lip risk exists, it is small. Use the lowest effective dose for the shortest period.

ADHD Medications

Stimulants do not increase major malformations. Slight links to low birthweight likely reflect ADHD itself.

If Pregnancy Is Discovered Unexpectedly

Do not stop medication(s) abruptly. Contact your doctor within 1–2 days.

Late Pregnancy and Delivery

SSRIs may cause short-lived neonatal adaptation symptoms in some infants.

PPHN (a serious newborn breathing problem) increases slightly:

• baseline: 1–2 per 1,000

• SSRI-associated: ~3 per 1,000

Quetiapine/olanzapine may justify earlier glucose testing.

Questions to ask:

• Does my dose need adjusting this trimester?

• What newborn monitoring should I expect after delivery?

Postpartum: The Risk Most People Underestimate

The postpartum period—marked by a sudden drop in estrogen and progesterone—is the highest-risk window for relapse or new-onset depression/anxiety.

Breastfeeding and Medication

Most psychiatric medications appear in breast milk at very low levels.

• Sertraline: lowest infant exposure

• Paroxetine: similarly low

• Escitalopram/citalopram: moderate but usually well tolerated

• Fluoxetine: longer half-life; can accumulate but still often appropriate

Lamotrigine transfers more but is typically tolerated. Lithium requires infant levels and kidney/thyroid monitoring.

Quetiapine and aripiprazole appear at low levels. Lorazepam is usually compatible. Methylphenidate transfers minimally.

Staying Well Off Medication

Some can remain well off medication—usually those with a single past episode, robust routines, and strong support.

Preparing for Postpartum

• What is the plan if symptoms return in the first two weeks?

• Who knows my early warning signs?

• How should doses change immediately after delivery?

Sleep protection is often as important as medication.

Medication Safety at a Glance 

Medication Class	Examples	Pregnancy Safety Summary	Notes / Key Points
SSRIs	Sertraline (Zoloft), Escitalopram (Lexapro), Fluoxetine (Prozac)	Strong safety data; no meaningful increase in major birth defects	Most studied antidepressants; first-line if medication is needed
SNRIs	Duloxetine (Cymbalta), Venlafaxine (Effexor)	Generally reassuring	Less extensive data than SSRIs, but no major safety concerns
Bupropion	Wellbutrin	Reassuring safety profile	May be preferred if fatigue or low energy is prominent
Mirtazapine	Remeron	Broadly reassuring	Limited data compared with SSRIs, but no known major risks
Tricyclics (TCAs)	Nortriptyline (Pamelor), Amitriptyline (Elavil)	Long track record; generally safe	Often used if patient has responded well in the past
Mood Stabilizers	Lithium	Some risk (e.g., Ebstein’s anomaly); careful monitoring required	Benefits may outweigh risks for severe bipolar disorder; dose adjustments needed
Antipsychotics	Aripiprazole, Risperidone, Quetiapine	Mostly reassuring; some data on metabolic effects	Used when necessary for severe mood or psychotic symptoms; monitor weight, blood sugar
Benzodiazepines	Lorazepam, Clonazepam	Some risk of neonatal adaptation syndrome and cleft palate; generally reserved for short-term use	Use lowest effective dose, ideally for brief periods

FAQ

What if my OB or pediatrician tells me to stop everything?

Ask them to coordinate directly with your psychiatrist.

How do I prepare for a medication-planning visit?

Bring your medication list. Ask for absolute numbers (“3% to 4%”) rather than only relative percentages.

Can I stay off medication postpartum?

Some can—but only with routine, therapy, protected sleep, and rapid-response planning.

What if I took medication before I knew I was pregnant?

This is very common. In early pregnancy, the effects of medications often follow an all-or-nothing pattern—meaning that most early exposures do not harm the baby. Do not stop any medication abruptly; instead, contact your healthcare provider for guidance.

Further Reading

MotherToBaby — Evidence-based fact sheets on medication safety in pregnancy and breastfeeding.

https://mothertobaby.org

LactMed — NIH database on how medications transfer into breast milk and affect infants. https://www.ncbi.nlm.nih.gov/books/NBK501922/

Postpartum Support International — Support, education, and provider referrals for perinatal mental health.

https://www.postpartum.net

MGH Center for Women’s Mental Health — Research summaries and clinical updates on reproductive psychiatry.

https://womensmentalhealth.org

Authorship

Frederic Kass, MD — Professor Emeritus of Psychiatry, Columbia University Medical Center; former Clinical Vice Chair, Department of Psychiatry Profile: Medical News Today

Erica Gettenberg, MD — Board-Certified in Adult, Child, and Adolescent Psychiatry; expertise in mood and anxiety disorders and ADHD. LinkedIn: Erica Gettenberg, MD

All vignettes are fictional and for educational purposes only. This is not a substitute for professional medical advice. Treatment decisions must be made with your clinicians based on your individual history and needs.